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Abstract
Background/Aims
We previously demonstrated that anthocyanin-rich bilberry extract (ARBE) inhibits IFN-γ-
induced signalling and downstream effects in human monocytic cells and ameliorates dis-
ease activity in ulcerative colitis (UC) patients. Here, we studied the molecular mechanisms
of ARBE-mediated effects in vitro and by analysing colonic tissue and serum samples of
UC patients treated with an oral anthocyanin-rich bilberry preparation during an open label
clinical trial.
Methods
Colon specimens obtained during an open pilot study using ARBE for the treatment of mild-
to-moderate UC were analyzed by immunohistochemistry. Cytokine levels in patients’
serum were quantified by ELISA. Cell culture experiments were performed using THP-1
monocytic cells.
Results
ARBE treatment inhibited the expression of IFN-γ-receptor 2 in human THP-1 monocytic
cells. Colon biopsies of UC patients who responded to the 6-week long ARBE treatment
revealed reduced amounts of the pro-inflammatory cytokines IFN-γ and TNF-α. Levels of
phosphorylated (activated) p65-NF-κB were reduced in these patients. Further, patients
with successful ARBE treatment featured enhanced levels of Th17-cell specific cytokine IL-
22 and immunoregulatory cytokine IL-10 as well as reduced serum levels of TNF-α and
MCP-1, but enhanced levels of IL-17A, in contrast to patients that did not reach remission
after ARBE treatment.
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Conclusions
Our data suggest a molecular mechanism underlying the anti-inflammatory effects of ARBE
treatment in UC patients by modulating T-cell cytokine signalling and inhibiting IFN-γ signal
transduction. These data are of particular interest, since ARBE is a promising therapeutic
approach for the treatment of IBD.
Introduction
Phenols are plant-derived molecules with anti-inflammatory, anti-oxidant, anti-carcinogenic,
anti-adipogenic and neuroprotective properties [1,2]. Chemically, they consist of one or more
(polyphenols) aromatic ring(s) with at least one hydroxyl group attached. Based on their chem-
ical structure, they are classified into two groups, flavonoids and non-flavonoids. Anthocyani-
dins form a crucial sub-class of dietary flavonoids and are widespread in fruits and flowers
where they account for the blue, purple and red colours. In these plant-derived forms they are
commonly conjugated to sugars or organic acids and consequently named anthocyanins [1,2].
Our regular diet contains a variety of natural phenols. Especially berries, red wines, leafy and
root vegetables and certain whole grain cereals comprise relative high amounts of anthocya-
nins. Due to their health-promoting and protective characteristics substantial interest in phe-
nols has emerged lately [3]. Multiple epidemiological studies demonstrated that polyphenol-
rich foods prevented diseases like coronary heart disease, certain types of cancer and inflamma-
tory diseases [4,5,6]. The benefits of polyphenols were originally attributed to their anti-oxidant
properties. Nevertheless, additional mechanisms such as direct interference with receptor-reg-
ulated signalling pathways and gene expression have been postulated [7,8,9].
Ulcerative colitis (UC), a sub-form of inflammatory bowel disease (IBD), is characterized by
a chronic and relapsing immune-mediated inflammation of the colon initiated by a dys-regu-
lated immune response to commensal intestinal microbiota and environmental factors in the
genetically susceptible host [10,11,12]. Prevalence and incidence of IBD have increased in west-
ern countries as well as in less developed countries where lower incidence rates were reported
previously [13]. The fact that numerous IBD patients are not satisfactorily treated with the
established treatment options or suffer from therapy-related side effects aggravates the burden
of IBD [14,15]. Thus, there is a need for more effective, well-tolerated and safe therapeutic
options.
Bilberries (Vaccinium myrtillus L.)–closely related to blueberries (Vaccinium corymbo-
sum)–have one of the highest natural anthocyanin content [16]. In a previous study [17] we
have confirmed the finding that anthocyanin-rich extracts reduce inflammatory gene expres-
sion in vitro [16,18,19]. Moreover, it has been demonstrated that bilberry ingestion and subse-
quently anthocyanin intake attenuates the severity of experimental colitis and diminishes pro-
inflammatory cytokine serum levels in animal models [20,21,22,23]. Based on these findings,
our group conducted an open label pilot study in patients with mild to moderate UC (approved
by the local ethics committee (EK-1733), trial not registered) [24]. In addition to their standard
medication, patients were treated with an anthocyanin-rich bilberry preparation. After 6
weeks, endoscopic and histologic disease activity and fecal calprotectin levels were significantly
reduced in the study participants, therefore anthocyanins represent a potential therapeutic
option in IBD. In this study, we aimed to further investigate the molecular processes underly-
ing the protective properties of anthocyanins. On one hand, we conducted in vitro experiments
with human monocytic THP-1 cells. On the other hand, we further analysed colon biopsies
Anthocyanins Affect T-Cell Cytokines
PLOS ONE | DOI:10.1371/journal.pone.0154817 May 6, 2016 2 / 17
Competing Interests: The authors have declared
that no competing interests exist.
and serum samples from UC patients who had participated in the above discussed open label
pilot study by Biedermann et al. [24] focussing on the expression of T-cell derived cytokines.
Materials and Methods
Reagents and Antibodies
All reagents were of analytical grade and obtained commercially. Monoclonal rabbit anti-
human phospho-STAT1 (Tyr701; D4A7), polyclonal rabbit anti-human STAT1 were obtained
from Cell Signaling Technologies (Danvers, MA, United States).
Human recombinant IFN-γ was obtained from Sigma (Sigma-Aldrich, St. Louis, MO,
United States). The anthocyanin-rich bilberry extract (ARBE) was manufactured by Kaden
Biochemicals, Symrise GmbH & Co (Holzminden, Germany) and was allocated as a powder
(25% anthocyanin content). This powder was dissolved in ddH2O to establish a stock suspen-
sion of 10 mg ARBE/ml. Due to sedimentation, the stock suspension was homogenized by
strong agitation during 30 minutes prior to each usage. A detailed analysis of the ARBE powder
can be found in S1 File.
Patient Samples
Intestinal tissue specimens were taken during the open label bilberry ingestion pilot study by
Biedermann et al. [24]. 13 patients with current mild to moderate UC underwent a first sig-
moidoscopy with biopsy taking 7 days prior to and 11 patients underwent a second sigmoidos-
copy at the last day of the six-week bilberry intake period as described in the aforementioned
study [24]. Patient’s serum was taken at the study visits 7 days prior to the beginning of the bil-
berry treatment (baseline = week 1) and from there on in a 2-week interval (i.e. week 3, week 5
and at the last day of the bilberry intake at week 7). Serum was frozen at -80°C and used for
ELISA experiments.
THP-1 Cell Culture, Vector Transduction, Phosphatase Inhibition and
Stimulation Protocols
Human monocytic THP-1 cells (DSMZ no. ACC 16, DSMZ, Braunschweig, Germany) were
cultured in RPMI 1640 medium (Life technologies, Gibco, Carlsbad, CA, United States) sup-
plemented with 10% fetal calf serum (FCS) at an approximate density of 0.5 to 1 x 106 cells/ml.
Cells were maintained in a 5% CO2 and 95% humidified incubator at 37°C. For experiments
without siRNA transfection, cells were seeded in 1 ml of FCS-free RPMI 1640 medium + 1%
Penicillin/Streptomycin per well at a density of 1 to 1.5 x 106 cells/ml at least 6 hours prior to
treatment.
PTPN2 siRNA transfection was performed using 100 pmol of a gene specific siRNA oligo-
nucleotide (Life technologies) and the Amaxa nuclefector system (Lonza, Walkersville, MD,
United States) according to the manufacturer’s instructions. After transfection, THP-1 cells
were cultured in a 12-well plate for 48 hours prior to treatment.
Pre-treatment with ARBE solution (composed of ARBE stock suspension and FCS-free
RPMI 1640 medium + 1% Penicillin/Streptomycin) with a final concentration of 10 μg/ml was
conducted 20 min before stimulation. Then, IFN-γ was applied in a previously validated con-
centration of 100 ng/ml ([25] and S1 Fig) for either 30 min (Western blot experiments) or 24 h
(qPCR experiments).
Inhibition of cellular phosphatases was induced by Na3VO4 (Sigma-Aldrich, S6508) accord-
ing to manufacturer’s recommendations and Gordon J.A. [26]. Na3VO4 in a final concentra-
tion of 0.5 mM was added to the THP-1 cells simultaneously with ARBE pre-treatment.
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Preparation of Whole Cell Lysates
THP-1 cells were washed twice with phosphate buffered saline (PBS) and lysed in M-PER
Mammalian protein extraction reagent (Pierce Biotechnology, Rockford, IL, United States)
containing protease inhibitors (Roche, Basel, Switzerland) for 45 min. After centrifugation (10
min at 13,000 g), cell lysate supernatants were assayed for protein content using a NanoDrop
spectrophotometer (NanoDrop ND1000; Pierce Biotechnology).
Western Blotting
Each lysate was mixed with loading buffer (NuPAGE1 4x LDS Sample Buffer (Life technolo-
gies), 500mM dithiothreitol and boiled for 5 min at 95°C. Separation of the proteins was per-
formed with SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Subsequently, the proteins
were transferred onto nitrocellulose membranes (Millipore, Billerica, MA, United States).
Membranes were blocked during 1 h with blocking solution (3% milk powder (C. Roth
GmbH+Co. KG, Karlsruhe, Germany) and 1% bovine serum albumin (BSA) (GE Healthcare,
PAA Laboratories GmbH, Pasching, Austria) in washing buffer (Tris buffered saline containing
1% Tween 20). Primary antibody was diluted in blocking solution (1:1000 for all experiments).
Membranes were incubated in primary antibody solution overnight at 4°C and then washed
with washing buffer for 30 min. Horseradish peroxidase (HRP)-labelled secondary anti-
mouse- or anti-rabbit-IgG-antibody (1:5000; sc-2005, sc-2004; Santa Cruz Biotechnologies,
Inc., Dallas, TX, United States) in blocking solution was added for 1 h and membranes were
washed again for 30 min. Immunoreactive proteins were detected using an enhanced chemilu-
minescence detection kit (Thermo Scientific, Rockford, IL, United States), and exposure on X-
ray films (GE Healthcare, Little Chalfont, UK). Films were scanned and intensity of the protein
bands determined using NIH ImageJ software. Densitometry values from proteins were nor-
malized to the corresponding values from non-treated controls. For STAT1, densitometry val-
ues from phosphorylated proteins were additionally normalized to the values from the
corresponding total proteins.
RNA Isolation and Complementary DNA Synthesis
THP-1 cells were washed with ice-cold phosphate buffered saline (PBS) and disrupted in RLT
buffer (Qiagen, Venlo, The Netherlands) and 1 M dithiothreitol solution. Total RNA was iso-
lated using RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions. RNA concen-
tration was measured by absorbance at 260 nm (NanoDrop ND1000). Complementary DNA
(cDNA) was synthesised using a High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA, United States) following the manufacturer’s recommendations.
Real-time Polymerase Chain Reaction (PCR)
Real-time PCR was performed using FAST qPCR Master Mix for Taqman Assays (life technol-
ogies) on a Fast 7900HT Real-Time PCR system using SDS Software (life technologies). Mea-
surements were performed in triplicate, human β-actin was used as endogenous control, and
results were analyzed by ΔΔCT method. The real-time PCR contained 45 cycles consisting of a
denaturing (95°C, 1 sec) and an annealing/extending (60°C, 20 sec) step. Gene expression
assays were all obtained from life technologies.
Immunohistochemistry
Immunohistochemistral procedures were performed using colon biopsies of eleven study par-
ticipants with UC. The biopsies were taken in the context of the bilberry study by Biedermann
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et al. [24]. Additionally, colon biopsies from healthy controls (n = 4), from UC patients with
active colitis (n = 1–2) and from UC patients with colitis in remission under conventional ther-
apy (n = 1–2) were investigated. A peroxide-based method on the formalin-fixed and paraffin-
embedded tissue specimens was applied. First, the tissue was deparaffinised with HistoClear1
(Chemie Brunschwig AG, Basel, Switzerland) and rehydrated in descending concentrations of
ethanol (100%, 96%, 70%), double-distilled water and PBS pH 7.2. In order to retrieve the tar-
get proteins and to avoid cross-linking reactions the biopsies were boiled in a citrate buffer solu-
tion (10mM, pH 6.0, DAKO, Glostrup, Denmark) in a 98°C hot water bath for 30 min. The
specimens were cooled down at room temperature and buffer traces were removed by washing
the tissue twice in PBS. For inactivation of the numerous endogenous peroxidases present in
intestinal tissue the specimens were incubated in a 0.9%H2O2 solution for 15 min at room tem-
perature. After another two washing steps in PBS the specimens were blocked with 1–3% BSA in
PBS for 1 h in a humidified chamber at room temperature. Subsequently, the tissue was incu-
bated with polyclonal rabbit anti-human IFN-γ (H-145) IgG (dilution 1:300; concentration
200 μg/ml; sc-8308, Santa Cruz Biotechnology), polyclonal Rabbit anti-human IFN-γ R1 (dilu-
tion 1:100; concentration 0.5 mg/ml; HPA029213, Sigma-Aldrich), polyclonal Rabbit anti-
human IFN-γ R2 (dilution 1:20; concentration 0.5 mg/ml; HPA001535, Sigma-Aldrich) poly-
clonal rabbit anti-human Stat1 (dilution 1:400; #9172S, Cell Signaling), monoclonal mouse anti-
human TNF-α (52B83) IgG1 (dilution 1:100; concentration 100μg/ml; sc-52746, Santa Cruz Bio-
technology), monoclonal rabbit anti-human phospho-NF-κB p65 (Ser536; 93H1) IgG (dilution
1:100; #3033S, Cell Signaling), monoclonal rat anti-human IL10 (JES3-12G8) IgG2a (dilution
1:100, concentration 0.5 mg/ml; Thermo Fisher, Pierce Biotechnology), monoclonal mouse anti-
human IL17A (aa1-75, 4K5F6) IgG2b,k (application 7 μg/ml, concentration 0.5 mg/ml; LS-B8323;
LifeSpan BioSciences, Inc., Seattle, WA, United States), or polyclonal rabbit anti-human IL22
(dilution 1:500, concentration 1.0 mg/ml; NB-100-737, Novus Biologicals, Littleton, CO, United
States), overnight at 4°C in a humidified chamber. After two rinsing steps in PBS the tissue was
incubated with corresponding secondary antibodies (ImmPRESSTM HRP anti-mouse (MP-
7402)/anti-rabbit (MP-7401) Ig (peroxidase) polymer detection kit from Vector laboratories,
Inc., Burlingame, CA, United States; goat anti-rat IgG-HRP, sc-2006, Santa Cruz Biotechnology)
for 1 h at room temperature in a wet chamber. After another two washing steps in PBS we used
the 3,30-diaminobenzidine (DAB) method according to the manufacturer’s instructions
(ImmPACTDAB peroxidase (HRP) Substrate, SK-4105, Vector laboratories) for visualization
and subsequently rinsed the tissue again in PBS. For counterstaining Mayer’s hemalaun solution
(Cantonal Pharmacy, Zurich, Switzerland) was applied and the tissue was then dehydrated in
ascending concentrations of ethanol and Histoclear1. The results of the staining were analyzed
using an AxioCamMRc5 (Zeiss, Jena, Germany) on a Zeiss Axiophot microscope (Zeiss) with
Axio Vision Release 4.7.2 software (Zeiss). For quantification, we performed blinded scoring and
rated with no (-), few (+), moderate (++) and intense (+++) staining.
Enzyme-linked Immunosorbent Assay (ELISA)
The participant’s serum was stored at -80°C. ELISA kits detecting human TNF-α (PK-EL-
63707), humanMCP-1 (PK-EL-64006), human IL-10 (PK-EL-62006), human IL-13 (PK-EL-
62306) and human IL-17A (PK-EL-62716) were obtained from Promokine (Heidelberg, Ger-
many), human IFN-γ ELISA kit (SEH00380A) was purchased at Qiagen. IL-22 was detected with
an ELISA set (DY-782-05) from R&D Systems, Inc. (Minneapolis, MN, United States). Assays
were carried out following the manufacturer’s instructions using a sample volume of 50 and
100 μl, respectively. Absorbance at stated wavelengths was detected on a BioTek-Synergy II
Multi-Mode Reader using Gen5.1.11 Software. All measurements were performed in duplicate.
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Statistical Analysis
Data are presented as means ± SEM for a series of n experiments. Data are expressed as relative
values of the respective control. Statistical analysis was performed by analysis of variance
(ANOVA) followed by Student-Newman-Keuls post hoc test. p values< 0.05 were considered
significant.
Results
ARBE prevents the IFN-γ-induced expression of IFN-γ receptor 2 in vitro
To study the molecular mechanisms of ARBE-induced reduction of IFN-γ signalling–mainly
STAT1 phosphorylation–as well as cytokine expression and secretion [17], human THP-1 cells
were treated with IFN-γ (100 ng/ml) and/or ARBE (10 μg/ml). As expected, IFN-γ treatment
reduced the expression of IFN-γ receptor 1 (IFN-γ R1), but enhanced levels of IFN-γ R2. Inter-
estingly, co-treatment with ARBE diminished the effect of IFN-γ treatment on the mRNA
expression of IFN-γ R1 (albeit its expression was still below the level in untreated cells) and
completely prevented IFN-γ-mediated induction of IFN-γ R2 (Fig 1A and 1B). (Raw data for
all experiments are shown in S2 File.) This is of particular interest, since IFN-γ R1 is important
for binding of IFN-γ to its receptor and IFN-γ R2 mediates signal transduction via the intracel-
lular JAK-STAT pathway activation after IFN-γ binding. The IFN-γ induced JAK-STAT path-
way mainly involves STAT1 phosphorylation, resulting in target gene expression [27,28].
We next assessed whether ARBE co-treatment might also impact STAT1 phosphorylation
by affecting the expression of SOCS1 and 3. As anticipated, IFN-γ treatment induced mRNA
levels of SOCS1 as well as of SOCS3. However, the IFN-γ-mediated induction of SOCS1
Fig 1. ARBE prevents the induction of IFN-γ receptor 2 (IFGR2) expression by IFN-γ. Administration of
100 ng/ml IFN-γ to THP-1 cells provoked a significant reduction of IFN-γ receptor 1 (IFGR1) that is crucial for
binding of IFN-γ to its receptor (A). On the other hand, IFGR2 that mediates intracellular signal transduction
was significantly induced upon the stimulation with IFN-γ (B). Interestingly, these effects were suppressed
when cells were co-treated with 10 μg/ml ARBE (IFN+ARBE). IFGR2 expression in untreated control cells
(Ctr) was comparable to co-treated cells (IFN+ARBE) (B). The expression of SOCS1 and 3 was induced by
IFN-γ stimulation while co-treatment with ARBE led to reduced expression of SOCS1 and 3 (C+D).
Significant results are marked as follows: * = p<0.05; ** = p<0.01; *** = p<0.001; n.s. = not significant. Error
bars depict SEM. Ctr = control, IFN = IFN-γ.
doi:10.1371/journal.pone.0154817.g001
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mRNA was completely abrogated in ARBE co-treated cells. A similar trend was also observed
for SOCS3 expression (Fig 1C and 1D).
A further mechanism of STAT1 regulation is via protein tyrosine phosphatase (PTP) activ-
ity. To assess whether ARBE might inhibit phosphorylation of STAT1 via activation of PTPs,
we used the PTP inhibitor Na3VO4. However, PTP inhibition had no impact on the ARBE-
mediated inhibition of IFN-γ-induced STAT1 phosphorylation (Fig 2, S2 Fig). Confirmatory,
siRNA-induced knock-down of protein tyrosine phosphatase non-receptor type 2 (PTPN2),
the nuclear phosphatase of STAT1, did not affect the ARBE-mediated inhibition of the IFN-γ-
induced effects on STAT1 phosphorylation either (S3 Fig), suggesting that PTPs do not play a
role for the ARBE-mediated inhibitory effects on IFN-γ-induced STAT1 phosphorylation.
IFN-γ and IFN-γ R2 expression in colon tissue decreases during ARBE
treatment in vivo
To further elucidate the anti-inflammatory properties of ARBE in the context of human dis-
ease, we performed immunohistochemical analysis of several biological markers in human
colonic biopsy specimens from 11 UC patients who had completed the bilberry ingestion study
of Biedermann et al. [24]. For each patient one biopsy before and one after 6 weeks of daily bil-
berry intake was analysed. Additionally, several cytokine concentrations were measured in the
participants’ serum by the ELISA method.
Since our previous findings revealed an impressive reduction of IFN-γ-related cytokine
expression/secretion upon ARBE treatment in vitro [17], we focused on the investigation of the
IFN-γ-JAK/STAT-pathway in this study. Analysis of IFN-γ staining revealed an–especially
submucosal–diminution of IFN-γ expression at the end of the bilberry intake period in patients
in remission, whereas no alteration was detectable in patients without clinical remission (Fig
3A, S4A Fig, S1 Table). In healthy control specimens, IFN-γ expression was generally low or
Fig 2. Inhibition of protein tyrosine phosphatases (PTPs) in THP-1 cells does not prevent ARBE-
mediated reduction of IFN-γ-induced STAT1 phosphorylation. Application of 0.5mMNa3VO4 (PTP
inhibitor) did not abrogate ARBE-induced reduction of IFN-γ-mediated STAT1 phosphorylation suggesting
that ARBE does not activate PTPs. Asterisks denote significant differences (* = p<0.05; ** = p<0.01; *** =
p<0.001). N = 3. Error bars depict SEM. Ctr = control, IFN = IFN-γ.
doi:10.1371/journal.pone.0154817.g002
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not evident (S5A Fig, S1 Table). On the other hand, IFN-γ serum concentrations–that were
generally very low–were not affected by ARBE treatment (S6A Fig). In addition, there was no
correlation between the IFN-γ serum concentrations and the clinical activity index (CAI).
At begin of the study, IFN-γ R2 expression was readily detectable in submucosal and intesti-
nal epithelial cells. Consistent with our cell culture data, six weeks anthocyanin intake reduced
IFN-γ R2 expression in the colon of the study participants to levels comparable to healthy con-
trols. Interestingly, this reduction was observed in all patients, independent of the remission
status (Fig 3B, S4B Fig, S1 Table). On the contrary, consistently high IFN-γ R2 expression was
observed in the active colitis and colitis in remission control biopsies (S5B Fig, S1 Table).
On the other hand, levels of IFN-γ R1 were low in intestinal biopsies taken before start of
the ARBE regimen (and in active colitis control biopsies). However, anthocyanin ingestion
resulted in submucosal accumulation of IFN-γ R1 positive cells–comparable to healthy con-
trols–, disregarding the remission status (Fig 3C, S4C Fig, S1 Table). Though, control speci-
mens from patients with colitis in remission upon conventional therapy did not show an
accumulation of IFN-γ R1 positive cells (S5C Fig, S1 Table).
We next analysed the expression of total STAT1 in the colon biopsies. Coherently with the
decline of IFN-γ expression, the number of total STAT1 expressing cells decreased to healthy
control levels during the study course in patients reaching remission (Fig 3D, S4D and S5D
Figs, S1 Table).
Fig 3. Reduced IFGR2 expression in colon tissue after 6 weeks of bilberry ingestion. Representative
pictures from colon biopsies taken before (week 1) and after six weeks of daily bilberry treatment (week 7)
from patients reaching remission or not. (A) shows specific staining for IFN-γ where a decline of IFN-γ
expression was registered for patients in remission only. A marked decline in IFGR2 expression was
provoked by ARBE ingestion not dependent on the remission status (B). A moderate enhancement in IFGR1
expression was detectable, both in patients that reached remission upon ARBE treatment as well as those
that did not (C). Expression of total STAT1 (especially in the L. propria mucosae) decreases in patients
reaching remission after 6 weeks of daily bilberry ingestion (D).
doi:10.1371/journal.pone.0154817.g003
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TNF-α expression in colon tissue declines depending remission status
Since our previous in vitro studies demonstrated that ARBE exerts pro- and anti-inflammatory
properties in response to TNF-α in human immune cells [17], we further investigated the
impact of dietary anthocyanin intake on TNF-α levels in colon tissue and serum. In patients
reaching remission, there was a decline in TNF-α expression to levels similar as in healthy con-
trols after six weeks of bilberry treatment, while in patients not reaching remission, no reduc-
tion in TNF-α expression was observed (Fig 4A, S7A Fig, S1 Table). As expected, TNF-α levels
in the active colitis control specimen were elevated, whereas they were lowered in a biopsy
from a UC patient in remission upon conventional therapy (S8A Fig, S1 Table). This indicates
that the reduction in TNF-α levels is dependent on remission status and not a direct result
from ARBE treatment. A similar trend was found in serum concentrations where TNF-α
decreased in patients in remission (n = 3; from 555 pg/ml down to 90 pg/ml), whereas they
stayed stable when remission was not achieved (n = 2; from 3041.72 pg/ml to 2967 pg/ml) (S6B
Fig).
TNF-α causes phosphorylation (activation) of the intracellular transcription factor NF-κB
which is the major signal transducer of TNF-α [29]. Therefore, we next performed a phospho-
p65-NF-κB staining (Fig 4B, S7B Fig, S1 Table). Reduction of phospho-p65-NF-κB positive
cells was observed in some patients reaching remission, yet levels were still above healthy con-
trol levels and comparable to the levels in colitis in remission upon conventional therapy (S8B
Fig, S1 Table).
Fig 4. A decrease in TNF-α expression is registered in patients reaching remission only. Images
illustrate representative pictures from colon biopsies taken before (week 1) and after (week 7) ARBE
treatment period. TNF-α expression regressed in patients that reached remission, whereas expression levels
remained stable when no remission was reached upon ARBE treatment (A). phospho-p65-NF-κB expression
at the end of the study was reduced in some but not all patients reaching remission under ARBE treatment
(B). Anthocyanins had no definite effect on the expression of IL-17A in colon tissue (C). Yet, IL-17A
expression levels were constantly higher than in healthy control colon tissue. An increase in colonic IL-22
expression was detectable within the study course in patients reaching remission (D). IL-10 expression levels
increase moderately during the study course (E), nearly approaching healthy control levels.
doi:10.1371/journal.pone.0154817.g004
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Bilberry intake reduced MCP-1 serum levels
Next, we analysed serum levels of the pro-inflammatory cytokine MCP-1 (Fig 5). Overall,
patients being in remission (n = 6) featured a decline in MCP-1 serum levels at the end of the
study (105 pg/ml down to 77 pg/ml), while patients not reaching remission (n = 2) at week 7
even revealed increased MCP-1 serum levels (74 pg/ml vs. 93 pg/ml). Remarkably, the two
patients with infliximab treatment before study inclusion started with relative high MCP-1 lev-
els, showed a transient rise and finally ended with the lowest MCP-1 concentrations among all
the participants.
Bilberry intake reduced Th17-specific cytokine protein expression while
their secretion was not affected
We next studied the impact of the daily bilberry intake with respect to the protein expression
of the typical Th17 cytokines IL-17A and IL-22 in the colon. As expected, UC patients featured
elevated IL-17A expression compared to healthy control colon tissue (Fig 4C, S7C and S9A
Figs, S1 Table). ARBE treatment did not result in a definite change in IL-17A expression, whilst
IL-17A serum levels increased when remission was reached (n = 5; 0,53 pg/ml vs 0,8 pg/ml) or
remained stable in patients without remission (n = 2) (S6C Fig).
IL-22 expression was enhanced under ARBE treatment when remission was reached. Yet,
active colitis and colitis in remission upon conventional therapy also featured elevated IL-22
Fig 5. Serum concentrations of the pro-inflammatory cytokine MCP-1 declined during the study course.
Analysis of MCP-1 serum levels was performed at the beginning of the bilberry intake (week 1) and subsequently in
intervals of 2 weeks (week 3, week 5 and week 7). Red dots are derived from patients that reached remission (n = 7)
at the end of the study whereas black dots belong to patients that did not reach remission (n = 3). Overall, a decline
in MCP-1 serum levels at the end of the study was registered only in patients reaching remission.
doi:10.1371/journal.pone.0154817.g005
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expression levels compared to healthy controls (Fig 4D, S7D and S9B Figs, S1 Table). Serum
IL-22 levels were rather stable during the study period (S6D Fig).
Bilberry ingestion enhanced IL-10 expression
We next addressed the impact of ARBE-enriched diet on IL-10 and IL-13. IL-10 colon expres-
sion either increased slightly or remained unaltered, yet levels remained under the healthy con-
trol levels (Fig 4E, S7E and S9C Figs, S1 Table). Although, IL-10 serum levels were generally
very low, an increase of the IL-10 serum concentrations was detected in 5 of 8 patients (S6E
Fig).
For IL-13, only serum concentrations were measured. Results were inconclusive since only
3 patients featured concentrations above the detection limits (S6F Fig).
Discussion
In this investigation on the biomolecular mechanisms underlying the anti-inflammatory prop-
erties of ARBE in UC patients, we found that ARBE suppresses IFN-γ-induced expression of
IFN-γ R2 in human monocytic cells (THP-1) and reduces expression of IFN-γ R2 in the intes-
tine of UC patients. Colon biopsies of UC patients undergoing successful ARBE treatment fur-
ther revealed a modified composition of T-cell-derived cytokines.
There is increasing evidence for the attenuating potential of polyphenols on IBD disease
severity in humans and in experimental colitis in mice/rats [20,21,22,24]. Here, we analysed
study material of the first non-controlled clinical intervention study investigating the efficacy
of an oral anthocyanin-rich bilberry preparation in 11 patients with mild to moderate UC per-
formed by Biedermann et al. [24]. This study reported significant beneficial effects on the
inflammatory disease activity. The aim of our investigations was to gain insights into the cyto-
kine expression of the colon and the serum cytokine levels during that 6-week long study
period, to ultimately permit conclusions on the molecular mechanisms of the applied bilberry-
derived anthocyanins.
The cytokine profile between UC and CD shows some characteristic differences. Based on
the levels of T cell-derived cytokines in IBD mucosa, it has traditionally been postulated that
CD is driven by an abnormal Th1 response, while UC has been thought to be a Th2-mediated
disease. Accordingly, higher amounts of IFN-γ –a Th1-derived cytokine–have been reported in
CD mucosa compared to UC whereas UC has been associated with elevated IL-5 and IL-13 lev-
els possibly derived from Th2 cells. However, this traditional view was to some extent rejected
when increasing evidence for the crucial role of Th17 cells emerged [30,31]. Th17 cells are
involved in the inflammation of both, UC and CD, and their presence in the colon is associated
with excessive expression levels of Th17 cytokines such as IL-17A, IL-17F and IL-22 [32,33].
In this study we investigated IFN-γ in context of UC–which seems contradictory at first
sight–since we found a remarkable inhibition of IFN-γ-derived cytokine expression and secre-
tion upon ARBE application in our preceding cell culture experiments [17]. Additionally, IFN-
γ remains an important cytokine in UC pathogenesis and elevated IFN-γ expression correlates
with disease activity [34,35,36].
IFN-γ effects are mainly elicited through the JAK/STAT pathway [28]. Here, we found that
ARBE inhibits the IFN-γ-induced expression of IFN-γ R2, which is the signal transducing part
of the IFN-γ receptor. Reduced levels of this molecule might well explain, how ARBE can act in
an anti-inflammatory manner by inhibiting IFN-γ-induced pro-inflammatory effects. Addi-
tionally, we found that ARBE does not promote expression of SOCS family proteins that are
responsible for the negative feedback mechanism of STAT activation [7].
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The importance of TNF-α in the pathogenesis of both, UC and CD, is fortified by the
impressive results of clinical trials targeting TNF-α [37]. Moreover, TNF-α levels correlate
with disease severity [31,38,39]. In this study, we demonstrated that daily bilberry ingestion
provoked a reduction in IFN-γ and TNF-α levels in the intestinal tissue in those patients who
reached remission while the levels did not decrease in those participants without remission.
Since reduction of IFN-γ and TNF-α was only observed in patients reaching remission after
the trial period, but not in patients consuming bilberry extract without reaching remission, this
effect might be the results of reduced disease activity and not a direct effect of the ARBE inges-
tion. This is further strengthened since patients in remission after conventional therapy show a
similar reduction of IFN-γ and TNF-α. Further, the serum levels of these cytokines were not
affected in a conclusive way. As ingestion of anthocyanin-rich bilberry extract resulted in
reduced expression of IFN-γ R2 and STAT1 not depending on the remission status, these
effects are likely to be mediated directly by ARBE treatment.
As described above, a specific subset of Th cells–Th17 cells–has been reported to play a key
pathogenic role in inflammatory conditions, including IBD. Th17 cells are characterized by
their ability to produce high amounts of IL-17A, IL-17F, IL-22, IL-10 and other cytokines cru-
cial for host defence against extracellular bacteria and fungi. In IBD, the intestinal mucosa is
characterized by a massive infiltration of Th17 cells and consequently reveals excessive
amounts of Th17-related cytokines [33,40]. However, neutralization of IL-17A (by antibody
treatment or genetic knockdown) leads to exacerbated intestinal inflammation in the dextran
sulphate sodium (DSS) colitis model [41,42]. Therefore, tissue-protective properties of Th17
cytokines are assumed. In our study, we observed an increase in IL-17A and IL-22 levels in the
intestinal tissue and/or serum after the bilberry intake period. This is of particular interest and
well in line with results from a clinical proof-of-concept trial using the anti-IL-17A monoclonal
antibody secukinumab. Here, inhibition of IL-17A by secukinumab has been demonstrated to
cause fatal effects in IBD patients [43]. All in all, more and more data suggest that Th17 cyto-
kines IL-17 and IL-22 might be rather protective for the intestine than deleterious. In our
study, we have analysed the effects of ARBE treatment in UC patients only and in our knowl-
edge no investigations on ARBE in CD patients have been conducted so far. Yet, there is
increasing evidence of the involvement of Th17 cells and their cytokines in the pathogenesis of
CD suggesting common molecular mechanisms in these two disease entities [44,45]. Therefore,
a potential benefit of ARBE in the treatment of CD patients remains to be assessed.
The regulatory T-cell (Treg) cytokine IL-10 is a crucial immunosuppressive cytokine pro-
duced by a variety of leukocytes and non-hematopoietic cells and features a central role in the
regulation of intestinal mucosal homeostasis and prevention of IBD [46,47]. However, accord-
ing to the literature inflamed intestinal tissue comprises increased numbers of mononuclear
IL-10 producing cells [48,49] accompanied by increased IL-10 serum levels [50]. Our findings
were in good accordance with these data, since we found an increase in IL-10 expression in
patients being in remission after treatment with ARBE. The induction of IL-10 might be an
important additional mechanism how ARBE exert anti-inflammatory effects in vivo.
In summary, we provide the first translational human study investigating the molecular
mechanisms of action of ARBE in UC patients. Our findings are based on an open label human
pilot study and therefore only in vitro data provided controlled results. On the one hand,
ARBE directly down-regulates IFN-γ-induced effects by inhibiting IFN-γ R2 expression. On
the other hand, ARBE seems to alter T-cell subsets in the intestine of UC patients. The small
number of participants impedes conclusive statements about the role of ARBE in UC disease
control and is a major drawback of this study. Yet, our findings are of importance for further
clinical use of anthocyanins and/or ARBE, since they demonstrated one–but probably not the
only—molecular mechanism how ARBE selectively modifies crucial immune mechanisms in
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the intestine. In conclusion, our data as well as the previous clinical trial data by Biedermann
et al. [24] reinforce the possible therapeutic use of ARBE in UC patients and warrant further
prospective, randomized and controlled clinical studies. Given the impressive reduction of
IFN-γ induced signalling cascades upon ARBE treatment, and the importance of IFN-γ in CD
pathogenesis, our study further provides evidence that ARBE treatment might also be a prom-
ising approach for the treatment of CD patients.
Supporting Information
S1 Fig. 100 ng/ml is an optimal concentration for eliciting robust IFN-γ signalling pathway
activation in THP-1 cells.We performed a concentration-action-curve stimulating THP-1
cells with 0 ng/ml, 1 ng/ml, 10 ng/ml, 100 ng/ml or 1000 ng/ml IFN-γ +/- 10 μg/ml ARBE.
Detection of phospho-STAT1 is optimal with application of 100 ng/ml IFN-γ.
(TIFF)
S2 Fig. Original uncropped and unadjusted Western blot from Fig 2. THP-1 cells were stim-
ulated either with 10 μg/ml ARBE, IFN-γ and/or 0.5mM or 5mMNa3VO4 (PTP inhibitor).
PTP inhibition did not abrogate ARBE-induced reduction of IFN-γ-mediated STAT1 phos-
phorylation. Ctr = control, IFN = IFN-γ, ACE = ARBE, I+A = IFN-γ + ARBE, p-
STAT1 = phospho-STAT1, tSTAT1 = total STAT1.
(TIFF)
S3 Fig. PTPN2 knockdown does not prevent ARBE-mediated reduction of IFN-γ-induced
STAT1 phosphorylation. For PTPN2 knockdown, THP-1 cells were transfected with 100
pmol PTPN2 siRNA 36 h before stimulation. Pre-stimulation with10 μg/ml ARBE lasted 20
min and subsequent stimulation with 100 ng/ml IFN-γ (IFN) lasted 30 min. Untreated cells
served as control group (Ctr). In THP-1 cells with PTPN2 knockdown co-stimulation with
IFN+ARBE still provoked reduced STAT1 phosphorylation. Yet, these results were not signifi-
cant.
(TIFF)
S4 Fig. Overview of immunohistochemical staining of different molecular markers where
detailed/enlarged images of Fig 3 are derived from. Representative pictures demonstrate
colon biopsies before (week 1) and after (week 7) ARBE treatment either for patients reaching
remission or not. A represents IFN-γ staining, B staining specific for IFGR2, C IFGR1 staining
andD shows total STAT1 expression. A more detailed view is shown in Fig 3.
(TIFF)
S5 Fig. IGFR2 expression in colon biopsy from control UC patient in remission is not sup-
pressed. Pictures demonstrate representative sections of control colon biopsies derived from
UC patients with active colitis, UC patients in remission under conventional therapy or from
healthy persons. Low IFN-γ expression in healthy control colon tissue is detectable (A). IGFR2
expression is elevated in active colitis and colitis in remission control colon, whereas low
expression is detectable in healthy controls (B). IGFR1 expression is hardly detectable in active
colitis and colitis in remission controls, whereas IGFR1 expression is detectable in healthy con-
trol biopsies (C). For STAT1 expression low to moderate results were found in healthy control
colon specimens (D).
(TIFF)
S6 Fig. Serum cytokine concentrations during the study course differ depending on the
remission status. Serum levels of different cytokines were measured each at week 1, week 3,
week 5 and week 7 of the study course. Red dots represent results from patients that reached
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remission, black dots belong to patients that did not attain clinical remission. ARBE treatment
did not affect the generally very low IFN-γ serum levels (n = 9) (A). TNF-α serum levels (only
5 participants featured serum concentrations above the detection level) decreased in patients
reaching remission (n = 3; from 555 pg/ml down to 90 pg/ml), whereas they stayed stable when
remission was not achieved (n = 2; from 3041.72 pg/ml to 2967 pg/ml) (B). IL-17A concentra-
tions increased when remission was reached (n = 5; 0,53 pg/ml vs 0,8 pg/ml) or remained stable
in patients without remission (n = 2) (C). IL-22 serum concentrations were stable during the
ARBE treatment period not depending on the remission status (n = 11) (D). IL-10 concentra-
tions were very low. Yet, a minimal increase was detectable in 5 of 8 patients (E). IL-13 mea-
surement was inconclusive since concentrations above the detection threshold were present in
only 3 patients (F).
(TIFF)
S7 Fig. Overview of immunohistochemical staining of different molecular markers where
detailed/enlarged images of Fig 4 are derived from. Representative pictures demonstrate
colon biopsies before (week 1) and after (week 7) ARBE treatment either for patients reaching
remission or not. Staining is specific for TNF-α (A), phospho-p65-NF-κB (B), IL-17A (C), IL-
22 (D) and IL-10 (E), respectively. A more detailed view is shown in Fig 4.
(TIFF)
S8 Fig. Elevated TNF-α expression in control biopsies from UC patients with active colitis.
These representative pictures from control colon biopsies are derived from UC patients with
active colitis or UC patients in remission under conventional therapy and healthy controls,
respectively. As expected, TNF-α expression in UC patients with active colitis is elevated,
whereas its expression is lowered when remission is attained. Healthy control colon depicts
low TNF-α expression (A). phospho-p65-NF-κB expression is low in active colitis and colitis
in remission control biopsies, while nearly no expression could be detected in healthy controls
(B).
(TIFF)
S9 Fig. Elevated IL-22 expression is found in control colitis. Pictures demonstrate represen-
tative sections of control colon biopsies derived from UC patients with active colitis, UC
patients in remission under conventional therapy or from healthy controls. IL-17A expression
in healthy colon is barely detectable (A). IL-22 expression levels are elevated in active colitis
control as well as in colitis in remission under conventional therapy biopsies, whereas healthy
controls feature lower IL-22 expression (B). IL-10 expression in healthy controls is readily
detectable (C).
(TIFF)
S1 File. Analysis of the ARBE powder used in these experiments.
(PDF)
S2 File. Raw data underlying cellular and ELISA experiments.
(XLSX)
S1 Table. Quantification of immunohistochemistry results performed by blinded scoring.
(XLSX)
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